

**Health Plan Best Practice
Chronic Lymphocytic
Leukemia (CLL)**


Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder (lymphoid neoplasm). It is characterized by a progressive accumulation of functionally incompetent B lymphocytes, which are usually monoclonal in origin.

CLL is the most common type of leukemia in adults¹

Average age at diagnosis is around 70¹


In the US it is estimated to have 20,000 new cases of CLL and 4,000+ deaths¹

AMCP'S MULTI-FACETED APPROACH TO IDENTIFY BEST PRACTICES



BEST PRACTICES

1 The choice of CLL therapy is based on patient and tumor characteristics and goals of therapy




Current Recommended Treatments in CLL


Mechanism of action	BTK inhibitor			BCL-2 inhibitor	Anti-CD20 monoclonal antibody	
Drug	Ibrutinib	Acalabrutinib	Zanubrutinib	Venetoclax	Obinutuzumab	Rituximab

2 Treatment toxicities are an essential consideration in the selection and switching of BTK inhibitors


Oncology Specialists Recommend Various First-Line CLL Treatments



Suggested Treatment Algorithm in Patients Intolerant of 1st Generation BTK Inhibitor



3 Evaluate the ROI of combination therapy in select CLL patient populations




4 Treatment adherence and impact on QoL are key factors when developing coverage policies

High medication adherence is needed to achieve optimal outcomes in CLL

Factors influencing adherence to oral therapies for CLL:⁴




5 Focus pathway development on frontline therapy, which is the highest percent of CLL patients



6 Minimal residual disease (MRD) testing is reserved for clinical trials and currently does not have a role in the routine care of patients with CLL



The top challenges for payers are related to costs, followed by the patient complexity



[View the Webcast On Demand](#)

References

1. Cancer.Net Leukemia- Chronic Lymphocytic - CLL Statistics. <https://www.cancer.net/cancer-types/leukemia-chronic-lymphocytic-ctl/statistics>
2. Adapted from Eichhorst et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2021 3223-33
3. Munoz et al. Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies. Oncologist. 2023 Apr 6;28(4):309-318.
4. Dashputre AA, et al. Divergent Patterns in Care Utilization and Financial Distress between Patients with Blood Cancers and Solid Tumors: A National Health Interview Survey Study, 2014–2020 J Manag Care Spec Pharm. 2020 Feb;26(2):186-196
5. Mato et al., Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" Clin Cancer Res. 2022 February 15; 28(4):603–608.